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Abstract
Background: Diarrhea is a major contributor to the burden of morbidity and mortality in children; it accounts for a
median of 11% of all deaths among children aged less than 5 years, amounting to approximately 0.8 million
deaths per year. Currently there is a dearth of literature exploring the effectiveness of antibiotics for diarrhea due
to Cholera, Shigella and cryptosporidiosis in children.
Methods: We reviewed the literature reporting the effect of antibiotics for the treatment of diarrhea due to
Cholera, Shigella and Cryptosporidium in children under five years. We used a standardized abstraction and grading
format and performed meta-analyses to determine the effect of the treatment with various antibiotics on mortality
and rates of clinical and bacteriological/parasitological failure. The CHERG Standard Rules were applied to
determine the final effect of treatment with antibiotics on diarrhea morbidity and mortality.
Results: For Cholera; the evidence was weak to recommend any effect on mortality. For Shigella; there was no
data on mortality; either all-cause or cause specific, hence we used clinical failure rates as a proxy for Shigella
deaths and propose that treatment of Shigella dysentery with antibiotics can result in a 82% reduction in diarrhea
mortality due to Shigella. For cryptosporidiosis; there was data on all-cause mortality but the evidence was weak
hence we used clinical failure rates as a proxy for mortality to estimate that antimicrobial treatment of diarrhea
due to cryptosporidiosis can result in a 54% reduction in mortality.
Conclusions: There is evidence to recommend antibiotic use for reduction of morbidity and mortality due to
Cholera, Shigella and Cryptosporidium. We recommend that more clinical trials should be conducted to evaluate the
efficacy and safety of first- and second- line drugs currently in use for treatment for diarrhea and dysentery in both
developing and developed countries.
Background
In 2011, 6.9 million children under five died, recording a
decrease of 5.1 million from that of 1990 [1]. The progress
is substantial but still a lot more is desired. Diarrhea is a
major contributor to the burden of morbidity and mortal-
ity in children; it accounts for a median of 11% of all
deaths among children aged less than 5 years, amounting
to approximately 0.8 million deaths per year [1]. Most of
this burden is concentrated in the developing countries of
Asia and Africa.
An important cause of diarrhea in children in the devel-
oping world; Cholera is a rapidly dehydrating disease that
can be fatal if untreated. Cholera was traditionally not
considered a notable problem in young children; however
data from endemic areas in the past two decades, suggests
that young children, especially those aged less than 5 years
are at the highest risk and bear the greatest burden of the
disease [2-5].The burden of Cholera has been increasing
steadily in the last decade and in the year 2010, the inci-
dence of Cholera saw an increase of 130% from 2000, with
an overall case fatality rate (CFR) of 2.38% and as high as
30% for some vulnerable groups living in high risk areas
[6]. The World Health Organization (WHO) recommends
rehydration as the mainstay of therapy for Cholera, anti-
microbial therapy is advocated only in the management
of severe cases-mostly interpreted as cases with “severe
dehydration”; to reduce the severity of illness, shorten the
duration of diarrhea and to reduce the duration of fecal
excretion [7]. While the recommendations of International
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(ICDDR, B) do not restrict use of antibiotics to only
“severe” cases and children with “some dehydration” who
continue to pass large volumes of stool, are also candidates
for antibiotic therapy [8,9].
Dysentery is a major cause of childhood morbidity and
mortality [10] and a variety of pathogens are responsible
for it including Shigella, Salmonella, E. Coli and Campy-
lobacter. Of these, Shigella is responsible for most of the
dysentery cases in the developing world [11]. The global
incidence of Shigella is estimated at 80-165 million epi-
sodes annually, with 99% of episodes in the developing
world [12]. A total of 69% of these episodes and 61% of
all deaths attributable to shigellosis involve children
under 5 years of age. According to previous estimates,
13.9% of infants and 9.4% of 1 to 4 year olds who are
hospitalized with shigellosis die each year [13], while a
recent review shows that shigellosis incidence is sub-
stantial and similar to the earlier estimate, but the
updated death estimate is 98% lower [14]. The WHO
recommends treating all cases of bloody diarrhea as sus-
pected shigellosis and recommends treatment of shigel-
losis with ciprofloxacin and with three second-line
antibiotics; pivmecillinam, azithromycin and ceftriaxone
[10].
Cryptosporidium is a zoonotic intracellular protozoan
parasite, which is an important cause of persistent diar-
rhea in children. It was included in the WHO Neglected
Diseases Initiative in 2004. Cryptosporidium may cause
life-threatening disease in people with AIDS and contri-
butes significantly to morbidity among children in devel-
oping countries [15]. It may account for up to 20% of
childhood diarrhea cases in developing countries and is
a potentially fatal complication of AIDS [16]. Cryptos-
poridium infection in early childhood is also associated
with poor cognitive function and failure to thrive [17].
Management of persistent infective diarrhea includes
rehydration, adequate diet, micronutrient supplementa-
tion and antimicrobials [18]. Of established efficacy in
immunocompetent patients, nitazoxanide is also useful
for immunocompromised patients [19].
We reviewed the scientific evidence available for the
use of antibiotics in the treatment of diarrhea due to
Cholera, Shigella and Cryptosporidium in children, as
well as differences in the effectiveness of various antibio-
tics. A Cochrane review [20] has evaluated the effective-
ness of antibiotics for Shigella in children and adults,
while the review by Traa et al [21] had evaluated the
effectiveness of antibiotics for dysentery and estimated a
cure rate of > 99%. We in this review have taken studies
with confirmed cases of Shigella only, so have estimated
the effect of antibiotics on Shigella cases. We have
reviewed the available literature and evaluated the qual-
ity of included studies according to the Child Health
Epidemiology Reference Group (CHERG) adaptation of
Grading of Recommendations, Assessments, Develop-
ment and Education (GRADE) criteria [22].
Methods
We systematically reviewed literature published up to
February 2012 to identify studies describing the effec-
tiveness of antibiotics for the treatment of Cholera,
Shigella and Cryptosporidium in children less than or
equal to 5 years. Following CHERG Systematic Review
Guidelines [22], we searched PubMed, Cochrane
Libraries, Embase, and WHO Regional Databases to
identify all published and unpublished clinical trials.
Additional studies were identified by hand searching
references from included studies.
We limited search to studies of antibiotic use in cases of
acute diarrhea due to Cholera, Shigella and cryptospori-
diosis. Search terms for Cholera included combinations of
“Cholera”, “diarrhea”, “antibiotics” and “antimicrobial”, for
Shigella, search terms included combinations of “shigell*”,
“antibiotic”, “dysentery” and “antimicrobial” and for Cryp-
tosporidium, search terms included combinations of “cryp-
tosporidi*”, “treatment” and “antibiotic”. No language or
date restrictions were applied in the search.
Inclusion criteria
Studies were included if they reported the effect of antibio-
tics on morbidity and mortality associated with diarrhea
due to the Cholera, Shigella and cryptosporidiosis in chil-
dren, as observed by clinical and bacteriological failure
and mortality. Only studies with a placebo group or no
antibiotic control group were included for Cholera and
Cryptosporidium diarrhea. For Shigella, there were no stu-
dies that compared antibiotics to placebo or a control
group, so studies with an antibiotic comparison group
were also included. Only studies with a confirmed diagno-
sis of the respective infection and on immuno-competent
patients were included. Our original inclusion criteria
included studies with children aged up to 5 years; however
since only one study reported outcome for this age group,
we expanded our inclusion criteria to include children up
to sixteen years of age.
Abstraction, analysis and summary measure
We abstracted data describing study identifiers and con-
text, study design and limitations, intervention specifics
and outcome effects into a standardized abstraction
form for studies that met the final inclusion criteria as
detailed in the CHERG Systematic Review Guidelines
[22]. Clinical failure was defined as incomplete resolu-
tion or marked lack of improvement in signs and symp-
toms. Bacteriological/parasitological failure was defined
as failure of clearance of the pathogen isolated from the
patient on admission to the study, during or by the end
of the treatment period.
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Each study was assessed and graded according to the
CHERG adaptation of the GRADE technique [22].
Randomized trials received an initial score of “high”. We
deducted a grade point for each study design limitation.
One- to two-point grade increases were allotted to stu-
dies with statistically significant strong levels of associa-
tion (>80% reduction).
Quantitative data synthesis
We conducted a meta-analysis for individual studies and
pooled statistics were reported as the relative risk (RR)
between the experimental and control groups with 95%
confidence intervals (CI). Mantel–Haenszel pooled RR
and corresponding 95% CI were reported or the DerSi-
monian–Laird pooled RR and corresponding 95% CI,
where there was an unexplained heterogeneity. All ana-
lyses were conducted using the software Review Man-
ager 5.1. Heterogeneity was quantified by Chi2 and I2,
which can be interpreted as the percentage of the total
variation between studies that is attributable to hetero-
geneity rather than to chance, a low p-value (less than
0.1) or a large chi-squared statistic relative to its degree
of freedom and I2 values greater than 50% were taken as
substantial and high heterogeneity. In situations of high
heterogeneity, causes were explored by sensitivity analy-
sis and random effect models were used.
We summarized the evidence by outcome, including
qualitative assessments of study quality and quantitative
measures, according to the standard guidelines. A grade
of “high”, “moderate”, “low” and “very low” was used for
grading the overall evidence indicating the strength of
an effect on specific health outcome according to the
CHERG Rules for Evidence Review [22].
Results
Cholera
We identified 374 titles from search conducted in all
databases. After screening titles and abstracts, we
reviewed 21 papers for the identified outcome measures
of interest (Figure 1). Only one study reported data
exclusively for children aged up to 5 years of age, so we
expanded our study population to include children up
to 16 years. Nine papers were reviewed and two [23,24]
included in the final dataset as only these two studies
had a suitable control or placebo group [23,24], whereas
all other studies had comparison groups of different
antibiotics. Both of the included studies were rando-
mized control trials and were conducted in Bangladesh.
One trial compared the antibiotics erythromycin, ampi-
cillin and tetracycline, while the other compared ery-
thromycin and trimethoprim/sulfamethoxazole TMP/
SMX against a placebo group.
In Table 1, we report the quality assessment of studies
by outcomes for antibiotic treatment of Cholera. Data
for clinical failure was based upon findings of two data
sets from one study [23]. There was a 63% reduction in
clinical failure, with a RR of 0.37 (95% CI: 0.19, 0.71).
Three datasets from one study were pooled for the out-
come of bacteriological failure showing a significant 75%
reduction with a RR of 0.25 (95% CI: 0.12, 0.53).
Shigella
We identified 103 titles from the search conducted in all
databases. After screening titles and abstracts, we
reviewed 48 papers for the identified outcome measures
of interest. Four papers [25-28] were included with data
for multiple antibiotics and more than one outcome
measure. We found three studies reporting clinical fail-
ure and four studies reporting bacteriological failure
rates (Figure 2). All except one [29] were from the
developing countries.
In Table 2, we report the quality assessment of stu-
dies by outcomes for antibiotic treatment of Shigella.
Five datasets from three studies reported on the out-
come of clinical failure. Two different antibiotics (piv-
mecillinam and ciprofloxacin) were used by these trials
and it resulted in a 82% reduction in clinical failure
with a RR of 0.18 (95% CI: 0.10, 0.33). While six data-
sets from four studies (pivmecillinam, ciprofloxacin
and ceftriaxone) reported on bacteriological failure
showing a reduction of 96% with a RR of 0.04 (95% CI:
0.01, 0.12).
Cryptosporidium
We identified 1375 titles from the search conducted in
all databases. After screening titles and abstracts, we
reviewed 21 papers for the identified outcome measures
of interest. Three [30-32] studies were included in the
final dataset with most papers contributing data for
more than one outcome measure (Figure 3). We found
two studies reporting clinical failure rates and three stu-
dies reporting bacteriological failure rates and all-cause
mortality was reported by two studies. All studies were
conducted in developing countries and were randomized
controlled trials.
In Table 3, we report the quality assessment of studies
by outcomes for antibiotic treatment of cryptosporidio-
sis. Antibiotic (Nitazoxanide) treatment resulted in a sig-
nificant 52% reduction in clinical failure rates with a RR
of 0.48 (95% CI: 0.30, 0.75) as reported by two studies
[30,31]. There was a 38% reduction in parasitological
failure with a RR of 0.62 (95% CI: 0.46, 0.83) and was
reported by three studies [30-32]. All-cause mortality
was reported by two studies [30,32] and it shows that
patients treated with antimicrobials (nitazoxanide and
spiramycin) resulted in an insignificant 76% reduction in
mortality with only seven events and a RR of 0.24 (95%
CI: 0.04, 1.45).
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Recommendation for the LiST model
Of the outcomes assessed for effect of antimicrobials on
diarrhea in children, we applied the CHERG rules for
evidence review to these outcomes. For Cholera, none
of the outcomes had events greater than 50, so this was
identified as insufficient evidence for LiST estimation
(figure 4). For Shigella; there was no data on mortality;
either all-cause or cause specific, hence we used clinical
failure rates as a proxy for Shigella deaths and propose
that treatment for Shigella dysentery with antibiotics
Figure 1 Search strategy flow chart for antibiotics treatment of cholera
Table 1 Quality assessment of trials of antibiotics for the treatment of cholera
Quality Assessment Summary of Findings
Directness No of events
No of
studies




Intervention Control Relative Risk
(95% CI)
Clinical Failure (Antibiotics vs. Placebo): Low Outcome Quality
01[23] RCT Only a
single study
In developing country Hospital based 8 20 0.37 (0.19,
0.71)
Bacteriological Failure (Antibiotics vs. Placebo): Low Outcome Quality
01[23] RCT Only a
single study
In developing country Hospital based 6 22 0.25 (0.12,
0.53)
Figure 2 Search strategy flow chart for antibiotic treatment of Shigella dysentery
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Table 2 Quality assessment of trials of antibiotics for the treatment of Shigella
Quality Assessment Summary of Findings
Directness No of events
No of
studies








Clinical Failure (Antibiotics): Moderate Outcome Quality
03
[25-27]
RCT No Control or placebo




All studies were conducted
in developing countries
Hospital based 50 0.18 (0.1,
0.33)b
Bacteriological Failure (Antibiotics): Low Outcome Quality
04
[25-28]
RCT No Control or placebo




All studies except one were
conducted in developing
countries
Hospital based 09 0.04
(0.01,
0.12)b
Figure 3 Search strategy flow chart for antibiotic treatment of Cryptosporidium diarrhea
Table 3 Quality assessment of trials of antibiotics for the treatment of cryptosporidium
Quality Assessment Summary of Findings
Directness No of events
No of
studies









Mortality – All Cause (Antibiotics vs. Placebo): Low Outcome Quality
02
[30,32]








Hospital based 1 6 0.24
[0.04,
1.45]a









Hospital based 14 32 0.48
(0.30,
0.75)a
Parasitological Failure (Antibiotics vs. Placebo): Moderate Outcome Quality
03
[30-32]








Hospital based 31 51 0.62
[0.46,
0.83]a
a= Fixed Effect Model
b= Random Effect Model
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results in an 82% reduction in diarrhea mortality due to
Shigella (Figure 5). For cryptosporidiosis; there was data
on all-cause mortality but the evidence was weak as
there were only seven events hence we used clinical fail-
ure rates as a proxy for mortality to estimate that anti-
microbial treatment of diarrhea due to cryptosporidiosis
results in a 54% reduction in mortality (Figure 6).
Discussion
This systematic review concludes that antibiotics when
given for Cholera reduce the clinical and bacteriological
failure rates; however the evidence for reducing morbid-
ity in children is insufficient to recommend antibiotic use
in all cases. It should also be noted that the studies
included in our review are more than a decade old and
hence conclusions drawn from these studies regarding
the antibiotics used may not reflect the current changing
patterns of antibiotic resistance among vibrio Cholerae
strains worldwide. The antibiotics used for Shigella dys-
entery included ciprofloxacin, pivmecillinam and cef-
triaxone and there is strong evidence that antibiotics
significantly reduce clinical failure and bacteriological
failure rates. It is evident that the use of antibiotics along
with appropriate rehydration therapy can lead to signifi-
cant reduction in morbidity and associated mortality.
The antibiotics used for Cryptosporidium in our review
Figure 4 Application of standardized rules for choice of final outcome to estimate effect of antibiotics in diarrhea due to cholera
Figure 5 Application of standardized rules for choice of final outcome to estimate effect of antibiotics in Shigella dysentery
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were nitazoxanide and spiramycin and we conclude that
antibiotics significantly reduced parasitological and clini-
cal failure, however, all-cause mortality, while evaluated
by two studies [30,32] reduced mortality by 76% but the
effect was insignificant and based on a small sample size.
Diarrhea due to Cholera is an important cause of
morbidity and mortality in children in the developing
world [33]. The cornerstone for Cholera therapy
remains prompt and adequate rehydration. Antibiotics
are known to shorten the course of illness, decrease
stool output, decrease the requirements of rehydration
fluid and decrease infectivity of the patient [29,34,35]. It
also leads to less home shedding and transmission to
households [35] which in turn would lead to less nur-
sing care and patients leaving the treatment center ear-
lier. This approach would maximize the effectiveness in
resource-limited settings while optimizing patient care.
There are concerns that over emphasis on the use of
antibiotics may lead to prescription in all cases of Cho-
lera, but training and education can handle this.
Although the evidence is weak as there are a few studies
evaluated and more research is needed, we propose that
antibiotics have a potential in moderate and severe Cho-
lera and there have been no adverse events identified by
any study.
Shigellosis is an acute and invasive infection that is com-
monly manifested as bloody diarrhea. Like Cholera, it
remains an important cause of morbidity and mortality in
children in the developing world. While rehydration and
adequate nutrition are important, antibiotic therapy is the
mainstay of treatment for Shigella dysentery which is
known to hasten clinical recovery and reduce the likelihood
of complications and death [10].
Cryptosporidium is responsible for persistent diarrhea
in children, causing a major impact on child health [36].
Disease varies in children with intact immune system
versus those with compromised immunity [37]. Initially
thought to be a disease of the immune-compromised,
immune-competent individuals can also acquire the
infection with mild-to-severe diarrhea lasting from sev-
eral days to weeks and our analysis has shown benefits
of antibiotic therapy in immune competent patients.
The studies contributing data in this review were
mostly conducted in developing countries hence increas-
ing the generalizability of the studies to children in low
and middle income countries with the highest diarrhea
mortality rates. However considering the variations in
antibiotic sensitivity among strains worldwide, our find-
ings may not be generalizable to all populations. Almost
all studies were conducted in a hospital setting where
treatment was monitored by hospital staff. Thus it is
possible that the therapeutic effect of antibiotics demon-
strated by the meta-analyses may not be completely
reproducible in a community or out-patient setting, due
to poor compliance with administration of the right
dosage at correct timings and for the prescribed time
period. Also adequate rehydration and subsequent mon-
itoring of the child for dehydration are extremely impor-
tant and this may not be performed properly by the
caretakers in outpatient or community setting, which
may not give the desired results, despite antibiotic use.
Diagnostic facilities are also not available in the commu-
nity, so future recommendations need to consider this.
With this review we have found sufficient evidence to
recommend antibiotic use for the reduction in mortality
and morbidity due to Shigella and Cryptosporidium
Figure 6 Application of standardized rules for choice of final outcome to estimate effect of antibiotics in diarrhea due to Cryptosporidium
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diarrhea. We have identified a need for further research
in this field and recommend that more clinical trials
should be conducted to evaluate efficacy and safety of
first- and second- line drugs currently in use for treat-
ment for diarrhea in both developing and developed
countries to strengthen the evidence of the recom-
mended antibiotics.
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